503 related articles for article (PubMed ID: 11191119)
1. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.
Puma JA; Sketch MH
J Am Osteopath Assoc; 2000 Nov; 100(11 Suppl):S8-12. PubMed ID: 11191119
[TBL] [Abstract][Full Text] [Related]
2. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
3. [Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
Umman B
Anadolu Kardiyol Derg; 2006 Apr; 6 Suppl 1():13-9. PubMed ID: 16613770
[TBL] [Abstract][Full Text] [Related]
4. Management of acute coronary syndromes with emphasis on new information for the treatment of ST-segment elevation acute myocardial infarction.
Lincoff AM
J Invasive Cardiol; 2002 Feb; 14 Suppl A():1A-2A. PubMed ID: 11847401
[No Abstract] [Full Text] [Related]
5. [Mexican Cardiology Society Guidelines on the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Cancún, Quintana Roo 15-16 November 2002. Cooperative Group of Consensus].
Lupi-Herrera E;
Arch Cardiol Mex; 2002; 72 Suppl 2():S5-44. PubMed ID: 12661524
[TBL] [Abstract][Full Text] [Related]
6. [Antithrombotic therapy for non-ST segment elevation myocardial infarction].
Hölschermann H
Hamostaseologie; 2006 May; 26(2):106-13. PubMed ID: 16676052
[TBL] [Abstract][Full Text] [Related]
7. Role of antiplatelet therapy in cardiovascular disease I: Acute coronary syndromes.
Cavendish JJ; Fugit RV; Safani M
Curr Med Res Opin; 2004 Nov; 20(11):1839-43. PubMed ID: 15537484
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of unstable coronary disease].
Préda I
Orv Hetil; 2002 Apr; 143(15):757-65. PubMed ID: 11979994
[TBL] [Abstract][Full Text] [Related]
9. Unstable angina and non-ST-segment myocardial infarction: an evidence-based approach to management.
Kou V; Nassisi D
Mt Sinai J Med; 2006 Jan; 73(1):449-68. PubMed ID: 16470325
[TBL] [Abstract][Full Text] [Related]
10. [National Registry of Acute Ischemic Coronary Syndromes (RENASICA). Mexican Cardiology Society. The RENASICA Cooperative Group].
Lupi Herrera E
Arch Cardiol Mex; 2002; 72 Suppl 2():S45-64. PubMed ID: 12661525
[TBL] [Abstract][Full Text] [Related]
11. Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies.
Goldstein P; Lapostolle F; Steg G; Danchin N; Assez N; Montalescot G; Charpentier S; Wiel E; Juliard JM
Eur J Emerg Med; 2009 Oct; 16(5):244-55. PubMed ID: 19318957
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
[TBL] [Abstract][Full Text] [Related]
13. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
14. Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?
Saucedo JF
Am J Cardiol; 2009 Sep; 104(5 Suppl):4C-8C. PubMed ID: 19695354
[TBL] [Abstract][Full Text] [Related]
15. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).
Lim MJ; Eagle KA; Gore JM; Anderson FA; Dabbous OH; Mehta RH; Granger CB; Fox KA; Spencer FA; Goldberg RJ;
Am J Cardiol; 2005 Oct; 96(7):917-21. PubMed ID: 16188516
[TBL] [Abstract][Full Text] [Related]
16. [Platelet aggregation and antiplatelet agents in acute coronary syndromes].
Collet JP; Choussat R; Montalescot G
Med Sci (Paris); 2004 Mar; 20(3):291-7. PubMed ID: 15067573
[TBL] [Abstract][Full Text] [Related]
17. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk.
Gibson CM
J Interv Cardiol; 2008 Dec; 21 Suppl 1():S3-9. PubMed ID: 19090934
[TBL] [Abstract][Full Text] [Related]
20. Do interventions provide additional benefit to drug treatment of acute coronary syndromes? A call for a reserved, watchful approach.
Gulba DC
Thromb Haemost; 1999 Aug; 82(2):953-61. PubMed ID: 10605809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
